Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132914 | 0.81 | DUT (0.37) | DUTBRD4BUB1 | |
| SCHEMBL31133122 | 0.79 | DUT (0.39) | DUTBUB1 | |
| SCHEMBL6076773 | 0.73 | PTGER1 (0.42) | — | |
| SCHEMBL15701789 | 0.72 | MEN1 (0.34) | DUT | |
| SCHEMBL31132618 | 0.70 | GABRA2 (0.38) | DUTRXFP1 | |
| SCHEMBL17428938 | 0.69 | DUT (0.36) | DUT | |
| SCHEMBL692594 | 0.69 | DGAT1 (0.45) | CASP3SENP8SENP7SENP6BRD4 | |
| SCHEMBL26631706 | 0.69 | DUT (0.32) | DUT | |
| SCHEMBL31132827 | 0.69 | DUT (0.38) | DUTBUB1 | |
| SCHEMBL21069375 | 0.69 | STK17B (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | DUT 4533/4885CASP3 4745/4885SENP8 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.